Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

<p>Recurrence per PDL1 and MPR</p>

Сохранить в:

Библиографические подробности
Главный автор:	Samuel Rosner (15054884) (author)
Другие авторы:	Joshua E. Reuss (15054887) (author), Marianna Zahurak (15054890) (author), Jiajia Zhang (15054893) (author), Zhen Zeng (15054896) (author), Janis Taube (15054899) (author), Valsamo Anagnostou (14961731) (author), Kellie N. Smith (15054902) (author), Joanne Riemer (15054905) (author), Peter B. Illei (15054908) (author), Stephen R. Broderick (15054911) (author), David R. Jones (15044613) (author), Suzanne L. Topalian (15031475) (author), Drew M. Pardoll (14953549) (author), Julie R. Brahmer (15054914) (author), Jamie E. Chaft (14937195) (author), Patrick M. Forde (15054917) (author)
Опубликовано:	2025
Предметы:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunotherapy Checkpoint blockade Lung Cancer
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы